TRENTAL

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
TRENTAL
Generic name
PENTOXIFYLLINE
Manufacturer
Validus Pharmaceuticals LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
b0d1d50f-9023-4e2f-889f-a5febba70fa5
SPL ID
5b329d9b-a63d-78d7-e063-6294a90a2032
Version
1
Effective date
2026-09-11
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:15:46
Harmonized routes table
Harmonized routes
ORAL

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS Clinical trials were conducted using either extended-release TRENTAL tablets for up to 60 weeks or immediate-release TRENTAL capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200-400 mg tid. The table summarizes the incidence (in percent) of adverse reactions considered drug related, as well as the numbers of patients who received extended-release TRENTAL tablets, immediaterelease TRENTAL capsules, or the corresponding placebos. The incidence of adverse reactions was higher in the capsule studies (where dose related increases were seen in digestive and nervous system side effects) than in the tablet studies. Studies with the capsule include domestic experience, whereas studies with the extended-release tablets were conducted outside the U.S. The table indicates that in the tablet studies few patients discontinued because of adverse effects. INCIDENCE (%) OF SIDE EFFECTS (Numbers of Patients at Risk) Extended-Release Tablets Immediate-Release Capsules Commercially Available Used only for controlled Clinical Trials TRENTAL (321) Placebo (128)​​​​​​​ TRENTAL (177) Placebo (138) Discontinued for Side Effect​​​​​​​ 3.1 0 9.6 7.2 CARDIOVASCULAR SYSTEM Angina/Chest Pain 0.3 - 1.1 2.2 Arrhythmia/Palpitation - - 1.7 0.7 Flushing - - 2.3 0.7 DIGESTIVE SYSTEM Abdominal Discomfort - - 4.0 1.4 Belching/Flatus/Bloating 0.6 - 9.0 3.6 Diarrhea - - 3.4 2.9 Dyspepsia 2.8 4.7 9.6 2.9 Nausea 2.2 0.8 28.8 8.7 Vomiting 1.2 - 4.5 0.7 NERVOUS SYSTEM Agitation/Nervousness - - 1.7 0.7 Dizziness 1.9 3.1 11.9 4.3 Drowsiness - - 1.1 5.8 Headache 1.2 1.6 6.2 5.8 Insomnia - - 2.3 2.2 Tremor 0.3 0.8 - - Blurred Vision - - 2.3 1.4 ​​​​​​​​​​​​​​​​​​​TRENTAL has been marketed in Europe and elsewhere since 1972. In addition to the above symptoms, the following have been reported spontaneously since marketing or occurred in other clinical trials with an incidence of less than 1%; the causal relationship was uncertain: ​​​​​​​Cardiovascular - dyspnea, edema, hypotension. Digestive - anorexia, cholecystitis, constipation, dry mouth/thirst. Nervous - anxiety, confusion, depression, seizures, aseptic meningitis. Respiratory - epistaxis, flu-like symptoms, laryngitis, nasal congestion. Skin and Appendages - brittle fingernails, pruritus, rash, urticaria, angioedema. Special Senses - blurred vision, conjunctivitis, earache, scotoma. Miscellaneous - bad taste, excessive salivation, leukopenia, malaise, sore throat/swollen neck glands, weight change. A few rare events have been reported spontaneously worldwide since marketing in 1972. Although they occurred under circumstances in which a causal relationship with pentoxifylline could not be established, they are listed to serve as information for physicians. Cardiovascular — angina, arrhythmia, tachycardia. Digestive — hepatitis, jaundice, cholestasis, increased liver enzymes; and Hemic and Lymphatic — decreased serum fibrinogen, pancytopenia, aplastic anemia, leukemia, purpura, thrombocytopenia. Immune system disorders — anaphylactic reaction, anaphylactoid reaction, anaphylactic shock. To report SUSPECTED ADVERSE REACTIONS, contact Validus Pharmaceuticals LLC at 1- 866-982-5438 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

adverse reactions table

<table cellspacing="0" width="70%" styleCode="Noautorules"> <col width="39%"/> <col width="15%"/> <col width="14%"/> <col width="15%"/> <col width="14%"/> <tbody> <tr> <td colspan="5" align="center"> <paragraph> <content styleCode="bold">INCIDENCE (%) OF SIDE EFFECTS</content> </paragraph> </td> </tr> <tr> <td rowspan="3" styleCode="Botrule Toprule" valign="bottom"> <paragraph> <content styleCode="bold">(Numbers of Patients at Risk)</content> </paragraph> </td> <td colspan="2" align="center" styleCode="Botrule Toprule"> <paragraph> <content styleCode="bold">Extended-Release Tablets</content> </paragraph> </td> <td colspan="2" align="center" styleCode="Botrule Toprule"> <paragraph> <content styleCode="bold">Immediate-Release Capsules</content> </paragraph> </td> </tr> <tr> <td colspan="2" align="center"> <paragraph> <content styleCode="bold">Commercially Available</content> </paragraph> </td> <td colspan="2" align="center"> <paragraph> <content styleCode="bold">Used only for controlled Clinical Trials</content> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Botrule"> <paragraph> <content styleCode="bold">TRENTAL (321) </content> </paragraph> </td> <td align="center" styleCode="Botrule"> <paragraph> <content styleCode="bold">Placebo (128)&#x200B;&#x200B;&#x200B;&#x200B;&#x200B;&#x200B;&#x200B; </content> </paragraph> </td> <td align="center" styleCode="Botrule"> <paragraph> <content styleCode="bold">TRENTAL (177) </content> </paragraph> </td> <td align="center" styleCode="Botrule"> <paragraph> <content styleCode="bold">Placebo (138) </content> </paragraph> </td> </tr> <tr> <td> <paragraph>Discontinued for Side Effect&#x200B;&#x200B;&#x200B;&#x200B;&#x200B;&#x200B;&#x200B;</paragraph> </td> <td align="center"> <paragraph>3.1</paragraph> </td> <td align="center"> <paragraph>0</paragraph> </td> <td align="center"> <paragraph>9.6</paragraph> </td> <td align="center"> <paragraph>7.2</paragraph> </td> </tr> <tr> <td colspan="5"> <paragraph> <content styleCode="bold">CARDIOVASCULAR SYSTEM</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Angina/Chest Pain</paragraph> </td> <td align="center"> <paragraph>0.3</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>1.1</paragraph> </td> <td align="center"> <paragraph>2.2</paragraph> </td> </tr> <tr> <td> <paragraph>Arrhythmia/Palpitation</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>1.7</paragraph> </td> <td align="center"> <paragraph>0.7</paragraph> </td> </tr> <tr> <td> <paragraph>Flushing</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>2.3</paragraph> </td> <td align="center"> <paragraph>0.7</paragraph> </td> </tr> <tr> <td colspan="5"> <paragraph> <content styleCode="bold">DIGESTIVE SYSTEM</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Abdominal Discomfort</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>4.0</paragraph> </td> <td align="center"> <paragraph>1.4</paragraph> </td> </tr> <tr> <td> <paragraph>Belching/Flatus/Bloating</paragraph> </td> <td align="center"> <paragraph>0.6</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>9.0</paragraph> </td> <td align="center"> <paragraph>3.6</paragraph> </td> </tr> <tr> <td> <paragraph>Diarrhea</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>3.4</paragraph> </td> <td align="center"> <paragraph>2.9</paragraph> </td> </tr> <tr> <td> <paragraph>Dyspepsia</paragraph> </td> <td align="center"> <paragraph>2.8</paragraph> </td> <td align="center"> <paragraph>4.7</paragraph> </td> <td align="center"> <paragraph>9.6</paragraph> </td> <td align="center"> <paragraph>2.9</paragraph> </td> </tr> <tr> <td> <paragraph>Nausea</paragraph> </td> <td align="center"> <paragraph>2.2</paragraph> </td> <td align="center"> <paragraph>0.8</paragraph> </td> <td align="center"> <paragraph>28.8</paragraph> </td> <td align="center"> <paragraph>8.7</paragraph> </td> </tr> <tr> <td> <paragraph>Vomiting</paragraph> </td> <td align="center"> <paragraph>1.2</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>4.5</paragraph> </td> <td align="center"> <paragraph>0.7</paragraph> </td> </tr> <tr> <td colspan="5"> <paragraph> <content styleCode="bold">NERVOUS SYSTEM</content> </paragraph> </td> </tr> <tr> <td> <paragraph>Agitation/Nervousness</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>1.7</paragraph> </td> <td align="center"> <paragraph>0.7</paragraph> </td> </tr> <tr> <td> <paragraph>Dizziness</paragraph> </td> <td align="center"> <paragraph>1.9</paragraph> </td> <td align="center"> <paragraph>3.1</paragraph> </td> <td align="center"> <paragraph>11.9</paragraph> </td> <td align="center"> <paragraph>4.3</paragraph> </td> </tr> <tr> <td> <paragraph>Drowsiness</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>1.1</paragraph> </td> <td align="center"> <paragraph>5.8</paragraph> </td> </tr> <tr> <td> <paragraph>Headache</paragraph> </td> <td align="center"> <paragraph>1.2</paragraph> </td> <td align="center"> <paragraph>1.6</paragraph> </td> <td align="center"> <paragraph>6.2</paragraph> </td> <td align="center"> <paragraph>5.8</paragraph> </td> </tr> <tr> <td> <paragraph>Insomnia</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>2.3</paragraph> </td> <td align="center"> <paragraph>2.2</paragraph> </td> </tr> <tr> <td> <paragraph>Tremor</paragraph> </td> <td align="center"> <paragraph>0.3</paragraph> </td> <td align="center"> <paragraph>0.8</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> </tr> <tr> <td> <paragraph>Blurred Vision</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>-</paragraph> </td> <td align="center"> <paragraph>2.3</paragraph> </td> <td align="center"> <paragraph>1.4</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.